Comparison
PT-141 vs TUDCA
Side-by-side of PT-141 and TUDCA. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
PT-141
PT-141 peptide (bremelanotide, Vyleesi): MC4R agonist for libido and erectile dysfunction. 1.75 mg subcutaneous, 30 to 60 min onset, 2 to 4 h half-life.
TUDCA
TUDCA is the taurine-conjugated form of ursodeoxycholic acid, a bile-acid molecule with replicated effects on liver function, ER stress, and bile flow.
Effects at a glance
PT-141
- •Cyclic 7-amino-acid synthetic peptide and melanocortin receptor agonist (MC4R-preferring)
- •FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in pre-menopausal women
- •Acts centrally on hypothalamic sexual-desire circuits rather than peripherally on vasculature
- •On-demand dosing: subcutaneous 1.75 mg approximately 45 minutes before sexual activity
- •Common adverse effects: nausea (~40%), flushing, headache, injection-site reactions, hyperpigmentation
- •Off-label male ED use is documented but not FDA approved; mechanism is distinct from PDE5 inhibitors
TUDCA
- •Bile-acid molecule (taurine-conjugated UDCA) with chemical chaperone activity at the endoplasmic reticulum
- •Established pharmaceutical use for cholestasis and primary biliary cholangitis at 500-750 mg/day
- •Reduces ER stress and stabilizes misfolded proteins; the mechanistic basis for emerging ALS / retinal applications
- •Modest improvements in NAFLD markers and insulin sensitivity at 500-1,750 mg/day in small trials
- •Mitochondrial protection signal in animal models drives the longevity-supplement positioning
- •Generally well-tolerated; mild GI effects are the main dose-dependent issue
Side-by-side
| Attribute | PT-141 | TUDCA |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Bremelanotide, Vyleesi | tauroursodeoxycholic acid, taurine-conjugated UDCA |
| Half-life (hr) ↗ | 2.7 | 4 |
| Typical dose (mg) ↗ | 1.75 | 500 |
| Dosing frequency | as needed (max once per 24 hours, max 8 per month) | daily, divided into 2 doses with food |
| Routes | subcutaneous | oral |
| Onset (hr) | 0.75 | 1 |
| Peak (hr) | 1.5 | 2 |
| Molecular weight | 1025.18 | 499.7 |
| Molecular formula | C50H68N14O10 | C26H45NO6S |
| Mechanism | Synthetic agonist of melanocortin receptors with preference for MC4R, expressed in hypothalamic and limbic circuits regulating sexual motivation. Engages central pathways distinct from peripheral PDE5-mediated vasodilation. | Bile-acid signaling via FXR/TGR5 receptors; chemical chaperone reducing ER stress and unfolded protein response; mitochondrial protection through reduced outer-membrane permeabilization. |
| Legal status | Prescription only as Vyleesi; FDA-approved 2019 for HSDD in pre-menopausal women. Compounded versions sold off-label for male sexual function are research-use-only grey market. | OTC dietary supplement (US); pharmaceutical in Italy and several Asian countries |
| WADA status | allowed | allowed |
| DEA / Rx | Rx only (not a controlled substance) for the FDA-approved Vyleesi formulation | OTC supplement |
| Pregnancy | Not recommended; contraindicated during pregnancy per Vyleesi label | Insufficient data for supplement use; UDCA used in cholestasis of pregnancy |
| CAS | 189691-06-3 | 14605-22-2 |
| PubChem CID | 9941379 | 9848818 |
| Wikidata | Q422059 | Q418751 |
Safety profile
PT-141
Common side effects
- nausea (~40%)
- flushing
- headache
- injection-site reactions
- hyperpigmentation (focal, gums, face, breasts)
- transient blood pressure increase (~6 mmHg systolic)
Contraindications
- uncontrolled hypertension
- established cardiovascular disease
- pregnancy
- naltrexone co-administration (reduces opioid efficacy due to MC receptor crosstalk)
Interactions
- naltrexone (oral): bremelanotide reduces oral naltrexone exposure significantly; avoid co-administration(major)
- antihypertensives: transient BP rise after bremelanotide can offset BP control(moderate)
- PDE5 inhibitors (sildenafil, tadalafil): no documented adverse interaction; mechanisms are non-overlapping(minor)
TUDCA
Common side effects
- mild GI upset
- diarrhea (dose-dependent)
- constipation (rare)
- nausea
Contraindications
- complete biliary obstruction
- pregnancy / lactation (insufficient supplement-dose data)
- active GI disease without medical supervision
Interactions
- cyclosporine, oral contraceptives, fat-soluble vitamins: modest absorption changes via altered bile-acid pool(minor)
- phenylbutyrate: synergistic for ALS use (Relyvrio combination); consult clinician(moderate)
Which Should You Take?
TUDCA comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. PT-141 is the right call when one of the conditionals below applies.
- → If your priority is sexual function, pick PT-141.
- → If your priority is libido, pick PT-141.
- → If your priority is liver function, pick TUDCA.
- → If your priority is healthspan extension, pick TUDCA.
Edge case: If you want to avoid research-only / gray-market sourcing, TUDCA is the more accessible choice.
Default choice: TUDCA. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for PT-141 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between PT-141 and TUDCA?
PT-141 and TUDCA differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, PT-141 or TUDCA?
PT-141 half-life is 2.7 hours; TUDCA half-life is 4 hours.
Can you stack PT-141 with TUDCA?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper